Page 177 - Vitamin D and Cancer

164 E. Gocek and G.P. Studzinski

Dohner K, Haas R, Dohner H (2004) Phase III study of all-trans retinoic acid in previously
untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18:1798–1803
6. Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi
U (2001) Safety of the synthetic retinoid fenretinide: long-term results from a controlled
clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 19:1664–1670
7. Jung SJ, Lee YY, Pakkala S, de Vos S, Elstner E, Norman AW, Green J, Uskokovic M, Koeffler
HP (1994) 1, 25(OH) –16ene-vitamin D3 is a potent antileukemic agent with low potential
2
to cause hypercalcemia. Leuk Res 18:453–463
8. Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88:582S–586S
9. Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the
vitamin D endocrine system. Endocr Rev 16:200–257
10. Ji Y, Wang X, Donnelly RJ, Uskokovic MR, Studzinski GP (2002) Signaling of monocytic
differentiation by a non-hypercalcemic analog of vitamin D3, 1, 25(OH) –5, 6 trans-16-ene-
2
vitamin D3, involves nuclear vitamin D receptor (nVDR) and non-nVDR-mediated path-
ways. J Cell Physiol 191:198–207
11. Collins ED, Bishop JE, Bula CM, Acevedo A, Okamura WH, Norman AW (2005) Effect of
25-hydroxyl group orientation on biological activity and binding to the 1alpha, 25-dihydroxy
vitamin D3 receptor. J Steroid Biochem Mol Biol 94:279–288
12. Aparna R, Subhashini J, Roy KR, Reddy GS, Robinson M, Uskokovic MR, Venkateswara
Reddy G, Reddanna P (2008) Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,
25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem
104:1832–1842
13. Danilenko M, Wang X, Studzinski GP (2001) Carnosic acid and promotion of monocytic
differentiation of HL60-G cells initiated by other agents. J Natl Cancer Inst 93:1224–1233
14. Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP (2003) Carnosic acid
potentiates the antioxidant and prodifferentiation effects of 1alpha, 25-dihydroxyvitamin D3
in leukemia cells but does not promote elevation of basal levels of intracellular calcium.
Cancer Res 63:1325–1332
15. Danilenko M, Studzinski GP (2004) Enhancement by other compounds of the anti-cancer
activity of vitamin D3 and its analogs. Exp Cell Res 298:339–358
16. Coffman FD, Studzinski GP (1999) Differentiation-related mechanisms which suppress
DNA replication. Exp Cell Res 248:58–73
17. Harrison LE, Wang QM, Studzinski GP (1999) Butyrate-induced G2/M block in CaCo-2
colon cancer cells is associated with decreased p34cdc2 activity. Proc Soc Exp Biol Med
222:150–156
18. Harrison LE, Wang QM, Studzinski GP (1999) 1, 25-dihydroxyvitamin D3-induced retarda-
tion of the G(2)/M traverse is associated with decreased levels of p34(cdc2) in HL60 cells.
J Cell Biochem 75:226–234
19. Wang QM, Studzinski GP, Chen F, Coffman FD, Harrison LE (2000) p53/56(lyn) antisense
shifts the 1, 25-dihydroxyvitamin D3-induced G1/S block in HL60 cells to S phase. J Cell
Physiol 183:238–246
20. Welsh J, Simboli-Campbell M, Narvaez CJ, Tenniswood M (1995) Role of apoptosis in the
growth inhibitory effects of vitamin D in MCF-7 cells. Adv Exp Med Biol 375:45–52
21. Li F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG (2005)
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in
two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385–1395
22. Myrthue A, Rademacher BL, Pittsenbarger J, Kutyba-Brooks B, Gantner M, Qian DZ, Beer
TM (2008) The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in
human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer
cells. Clin Cancer Res 14:3562–3570
23. Wang X, Studzinski GP (1997) Antiapoptotic action of 1, 25-dihydroxyvitamin D3 is associ-
ated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of
cytochrome c. Exp Cell Res 235:210–217